News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Zhanna Jumadilova, MD, MBA

Articles by Zhanna Jumadilova, MD, MBA

Persistence With Overactive Bladder Pharmacotherapy in a Medicaid Population

ByFadia T. Shaya, PhD, MPH,Steven Blume, MS,Anna Gu, MA,Teresa Zyczynski, PharmD, MBA, MPH,Zhanna Jumadilova, MD, MBA

July 15th 2005

Medical Costs After Initiation of Drug Treatment for Overactive Bladder: Effects of Selection Bias on Cost Estimates

ByNicole M. Nitz, PhD,Zhanna Jumadilova, MD, MBA,Theodore Darkow, PharmD,Jennifer R. Frytak, PhD,Tamara Bavendam, MD

July 15th 2005

Economic Impact of Extended-release Tolterodine versus Immediate-and Extended-release Oxybutynin Among Commercially Insured Persons With Overactive Bladder

BySujata Varadharajan, MS,Zhanna Jumadilova, MD, MBA,Prafulla Girase, MS,Daniel A. Ollendorf, MPH

July 15th 2005

Urinary Incontinence in the Nursing Home: Resident Characteristics and Prevalence of Drug Treatment

ByZhanna Jumadilova, MD, MBA,Teresa Zyczynski, PharmD, MBA, MPH,Barbara Paul, MD,Siva Narayanan, MS, MHS

July 15th 2005

Treatment of Overactive Bladder: A Model Comparing Extended-release Formulations of Tolterodine and Oxybutynin

ByEleanor M. Perfetto, PhD,Prasun Subedi, MS,Zhanna Jumadilova, MD, MBA

July 15th 2005

Latest Updated Articles

Persistence With Overactive Bladder Pharmacotherapy in a Medicaid Population
Published: July 15th 2005 | Updated:
Medical Costs After Initiation of Drug Treatment for Overactive Bladder: Effects of Selection Bias on Cost Estimates
Published: July 15th 2005 | Updated:
Economic Impact of Extended-release Tolterodine versus Immediate-and Extended-release Oxybutynin Among Commercially Insured Persons With Overactive Bladder
Published: July 15th 2005 | Updated:
Urinary Incontinence in the Nursing Home: Resident Characteristics and Prevalence of Drug Treatment
Published: July 15th 2005 | Updated:
Treatment of Overactive Bladder: A Model Comparing Extended-release Formulations of Tolterodine and Oxybutynin
Published: July 15th 2005 | Updated:

Trending on AJMC

Trump Announces Deals With Lilly, Novo to Cut Weight Loss Drug Prices

CMS Announces GENEROUS Model to Lower Medicaid Drug Prices

Medicare Advantage Reimbursement Structures Impact Home Health Delivery and Outcomes

Immune Checkpoint Inhibitors Safe to Use for NSCLC in Patients With HIV

FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk MM

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

© 2025 MJH Life Sciences^®

All rights reserved.